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ABSTRACT
Staphylococcus aureus infections are a major threat in healthcare, requiring adequate early-stage
diagnosis and treatment. This calls for novel diagnostic tools that allow noninvasive in vivo
detection of staphylococci. Here we performed a preclinical study to investigate a novel fully-
human monoclonal antibody 1D9 that specifically targets the immunodominant staphylococcal
antigen A (IsaA). We show that 1D9 binds invariantly to S. aureus cells and may further target other
staphylococcal species. Importantly, using a human post-mortem implant model and an in vivo
murine skin infection model, preclinical feasibility was demonstrated for 1D9 labeled with the near-
infrared fluorophore IRDye800CW to be applied for direct optical imaging of in vivo S.
aureus infections. Additionally, 89Zirconium-labeled 1D9 could be used for positron emission
tomography imaging of an in vivo S. aureus thigh infection model. Our findings pave the way
towards clinical implementation of targeted imaging of staphylococcal infections using the human
monoclonal antibody 1D9.
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Introduction
The rapid and accurate diagnosis of a bacterial infection is
important for the initiation of appropriate medical and
surgical management. Traditional diagnostic approaches
involve microbiological techniques, histologic staining
and, more recently, molecular techniques. However, these
approaches require sampling of infected tissues, which
involves invasive procedures that add cost and potential
morbidity, as uninfected tissue or implants are exposed to
bacteria from the skin microbiota and surgical environ-
ment. Also, culture-based diagnostic approaches are
inherently frought with issues of sampling error and con-
tamination. Since current diagnostic tests often take days
to deliver results, antibiotic therapy is frequently started
empirically, and this can lead to inadequate or incorrect
treatment, contributing to worse clinical outcomes. The
problems with current diagnosis of infection are particu-
larly relevant for infections caused by Staphylococcus
aureus, which is responsible for the majority of skin and
soft tissue infections, as well as invasive and life-threaten-
ing infections, such as cellulitis, pneumonia, osteomyelitis
and bacteremia.1 S. aureus is also a common cause of
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medical device and implant-related infections, which are
exceedingly difficult to treat because the bacteria form
biofilms on the foreign materials that inhibit the efficacy
of antibiotics. Rapid detection and treatment prior to the
seeding of implants and establishment of biofilm is essen-
tial. Moreover, the widespread emergence of methicillin-
resistant S. aureus (MRSA) strains, which are resistant to
multiple antibiotics,2,3 is causing substantial delays in
starting adequate antibiotics coverage. This highlights the
need for faster, more sensitive and noninvasive diagnostic
alternatives than are currently available.
Current noninvasive imaging modalities used to
localize infection foci include computed tomography,
positron emission tomography (PET) with fluorine-
18-fluorodeoxyglucose, and magnetic resonance imag-
ing. However, these approaches cannot accurately dif-
ferentiate between infected tissue and sterile
inflammation. Therefore, there have been intense
efforts to develop more targeted imaging techniques
by using bacteria-specific tracers, which typically con-
sist of a targeting moiety with affinity for bacteria
conjugated to an imaging agent for optical, optoa-
coustic or PET imaging.4,5 Promising tracers have
combined antibodies, antibiotics, antimicrobial pepti-
des, metabolizable compounds or particular ligands
with attached fluorophores or radioisotopes.4,6–8 How-
ever, the vast majority of these tracers has been
designed to detect infections caused by a broad spec-
trum of bacterial species, while relatively few studies
have explored species-specific tracers.9–12
We have recently provided proof-of-principle for the
use of antibiotic-based targeting probes labeled with
near-infrared (NIR) fluorophores for optical and optoa-
coustic imaging, demonstrating preclinical detection of
S. aureus infections.5,13 However, antibiotics generally
lack the ability to identify specific bacterial species as
most have broad affinity, binding indiscriminately to
Gram-positive and/or Gram-negative bacteria. Species-
specific tracers offer the potential to not only identify the
presence of an infection, but to define the causative
organism, thereby providing an actionable diagnosis that
could guide targeted antibiotic therapy. This is especially
relevant to invasive S. aureus infections, such as necrotiz-
ing pneumonia and endocarditis, or difficult-to-treat bio-
film-related infections. Such targets for staphylococcal-
specific imaging might include proteins exposed on the
bacterial cell surface.14–16 A well-conserved surface pro-
tein of S. aureus is the immunodominant staphylococcal
antigen A (IsaA).17–21 In a previous study, we developed
a fully human monoclonal antibody (humAb) against
IsaA, which was partially protective against S. aureus
infections in mouse models.22 In the present preclinical
study we investigated the target specificity of this anti-
IsaA humAb, named 1D9, using an extensive panel of
different staphylococcal isolates, and explored the feasi-
bility of using 1D9 conjugated with the NIR fluorophore
IRDye 800CW or the PET tracer 89Zr as an S. aureus-
specific tacer in a human post-mortem infection model
and in in vivo mouse models of S. aureus infection.
Results and Discussion
High target sensitivity of humAb 1D9 for S. aureus
A key feature of an effective targeting moiety for the spe-
cific detection of an infecting pathogen is the ability to
bind to the vast majority of different clinically related
isolates. A BLASTP analysis indicated that the isaA gene
was present in all of the 1912 different S. aureus isolates
for which sequences are available, with respective IsaA
proteins showing at least 98% amino acid sequence iden-
tity. In addition, the isaA gene was found to be conserved
in several other staphylococcal species. When S. aureus
isolates were excluded from the BLASTP results, signifi-
cant hits with at least 60% identity at the amino acid
sequence level were obtained for S. epidermidis (145), S.
argenteus (6), S. warneri (5), S. schweitzeri (3), S. simiae
(2), and S. haemolyticus (1). Additional identified staphy-
lococcal species with lower identity scores (<60%) for
IsaA included S. caprae, S. delphini, S. hominis, S. inter-
medius, S. lugdunensis, S. microti, S. pasteuri, S. pseudin-
termedius, S. schleiferi, S. schweitzeri, and S. simulans.
These findings suggest that the respective species pro-
duce IsaA proteins that may be detectable with 1D9. To
confirm these results, Western blotting analysis was per-
formed with 1D9. 1D9 detected IsaA production in well-
described MRSA strains, including USA300, Mu50,
MW2, N315, COL and MRSA252 (Fig. 1A). IsaA pro-
duction was also detected with 1D9 in the laboratory
strain NCTC8325-4 as well as additional clinical S.
aureus isolates from the University Medical Center Gro-
ningen (isolates A-Y; Fig. 1A, B). Of note, IsaA was
always detected in the cell fraction and in most (but not
all) growth medium fractions. To control for any off-tar-
get binding of 1D9 to different S. aureus proteins known
to bind to the Fc portion of human IgG1 (i.e., protein A
[Spa] and Sbi),15 cell and medium fractions from S.
aureus Newman wild-type and Dspa or Dspa Dsbi
mutant derivatives were tested for 1D9 binding. 1D9
bound to IsaA irrespective of the presence of Spa and Sbi
(Fig. 1C). From a test panel of other Staphylococcus spe-
cies, IsaA-specific signals were observed for two out of
four S. epidermidis isolates, two tested S. hominis isolates,
as well as an isolate of S. pettenkoferi and S. caprae
(Fig. 1C). IsaA expression was not detected in S. lugdu-
nensis, S. haemolyticus, S. capitis, S. warneri and S.
VIRULENCE 263
pasteuri, nor in Bacillus subtilis 168 or Escherichia coli
DH5a controls (Fig. 1C). As expected, no IsaA signal
was detectable in the cell and growth medium fractions
of an isaA deletion mutant (Fig. 1D). Taken together,
these findings imply that 1D9 can be used to specifically
detect cells of the vast majority of S. aureus isolates plus
a number of additional clinically-applicable staphylococ-
cal species.
Imaging of 1D9-800CW labeled bacteria in a human
post-mortem implant model
The ability of 1D9 to provide in vivo detection of S.
aureus was first assessed in a post-mortem model where
Whatman filter paper soaked with bacteria was
implanted subdermally on the tibia of a human cadaver
with subsequent skin closure.13 To enable NIR imaging,
1D9 was conjugated to the fluorophore IRDye 800CW,
and the resulting 1D9-800CW complex was added to
wild-type S. aureus bacteria. To assess the contribution
of IgG-binding proteins Spa and Sbi to the signal, S.
aureus mutant strains lacking both spa and sbi (Dspa
Dsbi) were also probed with 1D9-800CW. We addition-
ally included a S. aureus mutant strain lacking isaA
(DisaA) and S. epidermidis 1457 that are both negative
for binding 1D9 (Fig. 1). All cells incubated with 1D9-
800CW were thoroughly washed in phosphate-buffered
saline (PBS) and spotted in equal amounts (2.5 £ 108
Figure 1. IsaA expression in S. aureus and other staphylococcal species. Detection of IsaA production in (A) sequenced S. aureus strains
and (B) 25 clinical S. aureus isolates (A – Y) by Western blotting and immunodetection with 1D9-800CW. (C) Western blotting analysis
for IsaA detection in spa and spa sbi mutants of S. aureus Newman, E. coli DH5a, B. subtilis 168 and several different staphylococcal spe-
cies. Left panel, immunodetection of IsaA with unlabeled 1D9 and a secondary IRDye800CW-labeled goat anti-human antibody; right
panel immunodetection with 1D9-800CW. Purified His6-IsaA was used as a control. (D) Western blotting analysis to verify the absence of
IsaA production in S. aureus MS001 (DisaA) using 1D9-800CW for immunodetection. C, cell fraction; M, growth medium fraction. The
positions of molecular weight markers are indicated on the left, and the positions of IsaA, an IsaA degradation product (), Protein A
and Sbi are indicated on the right.
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CFU) onto a Whatman filter paper. NIR images of the
filter paper were recorded prior to and during »8 mm
subdermal implantation in the post-mortem model. As
shown in Fig. 2, the strongest NIR signal was observed
for wild-type S. aureus. A slightly lower signal was
observed for the Dspa Dsbi double mutant, indicating
that 1D9-800CW binding to IgG-binding proteins con-
tributed minimally to the observed signal. In compari-
son, the signal observed for the isaA mutant cells was
significantly lower, confirming that Spa and Sbi bind
relatively minor amounts of 1D9-800CW compared to
IsaA. Minimal signal was detectable for S. epidermidis
1457, which is consistent with the Western blotting data
in Fig. 1C. Importantly, the signal from the 1D9-800CW
bound to wild-type cells was clearly detectable upon
implantation and suturing of the skin, providing proof-
of-principle that 1D9 can be used for detection of sub-
dermal S. aureus infections in humans.
Noninvasive in vivo fluorescent imaging of S. aureus
infection with 1D9-800CW
To validate the potential use of 1D9-800CW for spe-
cific in vivo imaging of S. aureus infections, a murine
skin infection and inflammation model was used. In a
first group of mice, opposite flanks of each mouse
were inoculated intradermally with a bioluminescent
wild-type S. aureus SH1000 strain (wt) and the iso-
genic isaA mutant MS001 (DisaA). In parallel, a
group of control mice were inoculated in opposite
flanks with bioluminescent E. coli Xen14 (Ec) and
lipopolysaccharide (LPS) to evaluate any off-target
accumulation at a site of either an infection caused
by a bacterium that does not espress IsaA or sterile
inflammation. One day post-inoculation, 2.5 mg/kg
1D9-800CW was administered intravenously. Fluores-
cence and bioluminescence were recorded one day
prior to inoculation (t-2), one hour after inoculation
(t-1), immediately before 1D9-800CW administration
(t0), at 2/4/8 h after administration, and daily thereaf-
ter (t1-7) (Fig. 3). From day 1 onwards, significantly
higher fluorescent signal was localized in the flanks of
mice infected with the wt S. aureus strain compared
to the DisaA mutant (P<0.01), E. coli Xen14
(P<0.0001), or LPS (P<0.001) (Fig. 3A, B). The sig-
nificant difference observed for the wt and DisaA S.
aureus strains implies that, similar to the post-mor-
tem model (Fig. 2), 1D9-800CW binds to the IsaA
target rather than the IgG Fc-binding proteins Spa
and Sbi. Importantly, the stronger fluorescence signals
observed for the S. aureus isolates compared to the
fluorescence signals elicited by E. coli Xen14 or LPS
show that 1D9-800CW is specific for S. aureus, and
that S. aureus infection overall can be distinguished
from other causative infections or LPS-induced sterile
inflammation. However, an early peak of fluorescence
observed for mice inoculated with LPS indicates that
1D9-800CW does accumulate at early time points at
the site of sterile inflammation (Fig. 3B). This is pos-
sibly due to the Enhanced Permeability and Retention
(EPR) effect resulting from inflammation, or a higher
local density of neutrophils and hence Fc-receptor
binding of the 1D9 humAb. This effect was not
Figure 2. Human post-mortem implant model. For near-infra-
red fluorescent imaging of staphylococcal cells in a human
post-mortem model, overnight grown cultures of S. aureus
MS001 (DisaA), S. aureus SH1000 (wt), S. aureus Newman Dspa
Dsbi (Dspa Dsbi) and S. epidermidis 1457 in TSB (5 £ 108,
CFU) were collected, washed twice with PBS, resuspended in
100 ml of PBS, and incubated with 5mg of 1D9-800CW. Upon
20 min incubation at room temberature, cells were washed
twice with PBS and resuspended in 100 ml of PBS. Of this sus-
pension with fluorescently labeled cells, 50 ml aliquots were
spotted on filter paper strips (Whatman), and placed inside
sealed plastic wrapping. Visible light and fluorescence images
were recorded prior to and during surgical implantation onto
the distal tibia of a human post-mortem leg. Fluorescence
imaging was performed using an intraoperative clinical multi-
spectral fluorescence eXplorer Air camera (SurgVision BV).
Fluorescence signals were collected 0.5 sec (before implanta-
tion) and 0.2 sec (during implantation) with low binning and
excitation/emission wavelengths of 740/845 nm.
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observed when the mice were inoculated with E. coli,
suggesting that LPS induced a stronger inflammatory
response than E. coli. Importantly, the signal became
more specific from 2 days onwards. Further, the bio-
luminescence signals of the three bacterial strains
were not significantly different (Fig. 3C, D), showing
that differences in fluorescence signal were due to
specificity for S. aureus rather than the bacterial inoc-
ulum. Harvested organs on day 2 showed that fluores-
cence was mostly concentrated in the liver, with no
appreciable signals in the spleen, kidneys, bladder or
heart (Fig. 3E), which is consistent with the known
clearance of antibodies by the liver. Of note, all biolu-
minescence signals at sites of infection decreased over
Figure 3. In vivo IsaA-specific optical imaging of S. aureus infection with 1D9-800CW. Six to eight weeks old C57BL/6 female mice were
shaved on the flanks and back, and mid-logarithmic growth phase S. aureus SH1000 lux (wt) and DisaA S. aureus MS001 lux (5 £ 107
CFUs in 100 ml of sterile saline) were each injected intradermally into opposite flanks of each mouse (n = 7 performed over 3 indepen-
dent experiments). In a second group of mice, E. coli Xen14 (Ec; 5 £ 107 CFUs in 100 ml of sterile saline) and lipopolysaccharide (LPS;
1 mg/kg in 100 ml of sterile saline) were injected intradermal into opposite flanks of each mouse (n = 4 performed over 1 experiment).
Inoculations were performed on t-1. Control images were recorded 1 day prior to inoculation (t-2). One day post bacterial inoculation (t0)
or 1 h after LPS injection, 1D9-800CW (2.5 mg/kg in 100 ml sterile saline warmed to 37C) was injected retro-orbitally and images were
subsequently recorded at different time points as indicated. The fluorescent (total radiant efficiency [photons/s]/[mW/cm2]) and biolu-
minescent signals (total radiance [photons/s]) were measured with a 1.2 £ 1.2 cm region of interest (ROI) centered over the site of skin
infection/inflammation. (A) NIR fluorescence images of representative mice were collected at 0.5 sec with medium binning and excita-
tion/emission wavelengths of 740/845 nm. (B) Mean total radiant efficiency (photons/s)/(mW/cm2) § s.e.m. of the in vivo fluorescent
signals. (C) Bioluminescence images of representative mice were collected for 60 sec with medium binning. (D) Mean total flux (pho-
tons/sec) § s.e.m. (logarithmic scale) of in vivo bioluminescent signals. (E) Representative NIR fluorescence images of different organs
collected on day 2 for assessment of 1D9-800CW accumulation. In panels B and D, variations are indicated with error bars and statisti-
cally significant differences with different symbols for each curve ( = P<0.05; y = P<0.01; z = P<0.001).
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time, which could relate to reduced growth, loss of
the pLux plasmid that was used to make the bacteria
bioluminescent and/or bacterial clearance. For exam-
ple, we have previously shown that luminescence of
the bacteria is significantly reduced once they reach
the stationary phase of growth.13 In contrast, the 1D9
antibody will bind to IsaA irrespective of whether the
bacteria are dead or alive. This would explain why a
stable signal for 1D9-800CW was observed at time
points post infection where the bioluminescence sig-
nal had disappeared. In addition, culturing of infected
mouse tissue showed that some S. aureus CFU had
lost the pLux plasmid (data not shown). Altogether, it
seems that the loss of luminescence was probably
both related to reduced growth and loss of the pLux
plasmid. Yet, it cannot be excluded that a slight
decrease in bacterial numbers by immune clearance
contributed to the loss of the luminescence signal at
the site of infection.
Since the above set of experiments involved two
groups of mice inoculated in parallel, an independent
experiment was performed where opposite flanks of the
same mice were inoculated intradermally with a biolumi-
nescent community-acquired MRSA strain (SAP231)
and E. coli Xen14. In both of these bacterial strains, the
lux genes for bioluminescence are stably integrated into
the chromosome and are thus present in all progeny.
Similar to the prior experiment, the fluorescent signals of
1D9-800CW were higher at the site of the S. aureus
infection compared with the E. coli infection (Fig. 4A,
B), showing the specificity of 1D9-800CW for S. aureus.
Likewise, the bioluminescent signals of the infecting bac-
teria both decreased over time (Fig. 4C, D), suggesting
reduced bacterial growth and/or clearance. A noteworthy
observation was that the 1D9-800CW signal relating to S.
aureus infection was highly stable over 7 days, which is
in line with the known half-life of IgG1 humAbs of 6–
8 days in mice. Since the half-life of IgG1 humAbs in
humans is »3 weeks, our findings imply that this partic-
ular probe can be used over several days upon adminis-
tration, which is a clear advantage for potential clinical
applications.
Figure 4. Distinction of S. aureus and E. coli infection by optical imaging with 1D9-800CW. Mice were inoculated intradermally in oppo-
site flanks with bioluminescent S. aureus SAP231 (SAP) and E. coli Xen14 (Ec) as described for Fig. 3. Images were recorded at different
time points pre and post intravenous administration of 2.5 mg/kg 1D9-800CW. (A) NIR fluorescence images of representative mice were
collected with excitation/emission wavelengths of 740/845 nm. (B) Mean total radiant efficiency (photons/s)/(mW/cm2) § s.e.m. of the
in vivo fluorescent signals. (C) Bioluminescence images of representative mice. (D) Mean total flux (photons/sec) § s.e.m. (logarithmic
scale) of in vivo bioluminescent signals. In panels B and D, variations are indicated with error bars and statistically significant differences
with different symbols for each curve ( = P<0.05; y = P<0.01; z = P<0.001).
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Previously, we have shown that the antibiotic vanco-
mycin labeled with IRDye800CW (i.e., vanco-800CW)
also allows for highly specific noninvasive in vivo detec-
tion of infecting staphylococci. However, vanco-800CW
detects a broad spectrum of Gram-positive bacteria.13 In
contrast, a positive signal obtained with 1D9-800CW is
diagnostic for potentially virulent staphylococci.
Noninvasive in vivo PET imaging of S. aureus
infection with 89Zr-1D9
NIR fluorescence imaging of infection is appealing due to
its speed, noninvasiveness and high resolution. In addi-
tion, it does not involve the use of radioactive isotopes,
which makes it less expensive and more flexible than PET
or single-photon emission computed tomography imag-
ing, as well as circumventing the burden of ionizing radia-
tion.4 Despite these advantages, one major drawback of
NIR fluorescent imaging is the limited signal penetration
through tissue, which is about 1 cm due to light absorp-
tion and scatter.4 For these reasons, we also explored the
possibility of applying 1D9 to whole-body PET imaging
to see if this modality would allow the high-sensitivity
delineation of deeper-seated infections with clinical signifi-
cance. Thus, 1D9 was labeled with 89Zr, which has a half-
life of 78.4 h. Similar to the experiments shown in
Fig. 3A, B, opposite flanks of each mouse were inoculated
with wt S. aureus SH1000 and the isogenic isaA mutant
MS001 (DisaA). At 1 day post-infection, 0.7 mg/kg of
89Zr-1D9 was administered and PET images were
recorded on days 3, 5, and 7. As shown in Fig. 5A, B,
89Zr-1D9 revealed a specific accumulation at the site of
infection, with a significantly higher intensity for the
infection caused by wild-type S. aureus compared to the
infection by IsaA-deficient S. aureus. Statistically signifi-
cant differences between the specific and control infec-
tions were detected for 3 days. However, due to the
limited half-life of 89Zr, imaging was only possible for up
to 7 days. Of note, Fig. 5A shows a strong signal in the
body, which is consistent with the data presented in
Fig. 3E where the accumulation of 1D9-800CW in the
liver is shown. For potential clinical applications in the
future, the known clearance of antibodies by the liver may
thus represent a challenge if one wishes to detect specific
signals of endocarditis or other infections near high-
uptake organs, such as the liver. However, this is likely to
represent less of a problem, if any, for the imaging of
infections at body sites distant from the liver.
Future perspectives
Here we present the humAb 1D9 as a highly specific
probe for both fluorescence and PET imaging of staphy-
lococcal infections. The high specificity of 1D9 is demon-
strated by longitudinal measurements in mouse infection
models with extensive controls, in particular recombi-
nant IsaA-deficient S. aureus, the Gram-negative bacte-
rium E. coli and purified LPS. Thus, off-target
accumulation of 1D9 at sites of inflammation and infec-
tion, e.g. due to increased blood flow and vascular per-
meability, may be ruled out. We consider it important
that 1D9 is compatible with PET imaging modalities,
because this may permit a faster introduction into the
clinic as PET facilities are widely available in hospitals
around the globe. Further, our experiments suggest the
feasibility of 1D9 applications in optoacoustic imaging,
Figure 5. In vivo IsaA-specific PET imaging of S. aureus infection with 89Zr-1D9. Mice were inoculated intradermally in opposite flanks
with either S. aureus SH1000 (wt) or S. aureus MS001 (DisaA) as described for Fig. 3 (t-1). One day post inoculation (t0), 0.7 mg/kg
89Zr-
1D9 was administered intravenously and images were subsequently recorded at different time points as indicated. List-mode data were
acquired using a gamma-ray energy window of 350 to 750 keV and a coincidence timing window of 6 ns. PET imaging data were cor-
rected for detector non-uniformity, dead time, random coincidences, and physical decay. For all static images, scan time was between
10 and 20 min. (A) PET images of representative mice [arrows = wt infection; arrowheads = DisaA infection;  = knee joint; & = heart].
(B) PET total activity (mCi) at the site of infection. In panel B, variations are indicated with error bars and statistically significant differen-
ces with an asterisk ( = P<0.05).
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which has a significantly better tissue penetration (> 8
cm) than light (»1 cm).4,5 This relates to the fact that
agents used in optoacoustic imaging, like indocyanine
green, absorb light of a particular wavelength and subse-
quently undergo thermo-elastic expansion. In turn, this
results in the emission of ultrasonic pressure waves,
which have much longer wavelengths than light and
higher tissue penetration. Importantly, such ultrasonic
signals are detectable with special sensors.
The need for rapid noninvasive modalities for infection
imaging is highlighted by recent publications on a variety of
probes that, together, allow in vivo detection of a broad
spectrum of pathogens. For instance, these include probes
based on antibiotics,4,23 maltodextrin,24 prothrombin,25 oli-
gonucleotides,26 the bacteriophage M13,12,27 and concanav-
alin A.28 In this study, the 1D9 probe was evaluated as a
novel and alternative antibody-based probe with the highest
target specificity for S. aureus. 1D9 labeled with the NIR flu-
orophore IRDye800CW could be used to continuously
monitor infecting bacteria over a period of at least 7 days
using in vivo fluorescence imaging. For the imaging of
deeper-seated infections, 1D9 labeled with 89Zr can be used
in conjunction with whole-body PET imaging.We therefore
conclude that the humAb 1D9 provides new targeted and
specific diagnostic imaging tracers for S. aureus infections.
Novel diagnostic technologies, especially next-genera-
tion DNA sequencing, are becoming increasingly popular
tools for the detection of infections. However, next-genera-
tion sequencing is probably best-suited for the detection of
superficial infections. For detection of deep-seated infec-
tions, the invasive sampling that would be required could
be dangerous and is subject to the uncertainties of incor-
rect sampling and contamination. A potential advantage
of using noninvasive imaging in conjunction with a spe-
cific monoclonal antibody probe, such as 1D9, is that it
may allow the detection of both superficial and deeper
seated infections. The latter is particularly the case when
the antibody is labeled with a PET tracer, as exemplified in
the present study with 89Zr-1D9. Given the increasingly
common usage of immunoPET imaging, the application
of this tool with microgram amounts of antibody could
certainly be justifiable in many cases of infection even
though the general use of radioactive labels should be
restrained. Importantly, not all possible diagnostic applica-
tions of the 1D9 antibody will necessarily require radioac-
tive labels. For instance, it is well-conceivable that a
fluorescently labeled antibody, like 1D9-800CW, is suitable
to guide surgery through intra-operative imaging of infec-
tions as is currently explored in cancer imaging.4 Further,
foci of infection could be detectable by the use of fluores-
cently labeled antibodies in combination with endoscopy.
Despite the promising results obtained in the present
study, the application potential of our humAb 1D9 needs
to be assessed in future ex vivo or in vivo studies. For exam-
ple, it is currently hard to predict whether the specificity of
1D9 is high enough to discriminate sterile inflammation
from infection, especially at early time points after the onset
of infection. In addition, it is not yet known how competing
circulating antibodies of the host will impact on the effi-
ciency of imaging with labeled 1D9. The latter potential
problem can probably be overcome with PET tracers (e.g.
89Zr), since part of the appeal of radioactivity is that low
antibody binding can still lead to the emission of a suffi-
ciently strong signal to allow accurate measurements.
Another important questions relates to the need for parallel
diagnostics to detect infections caused by pathogens other
than S. aureus. In this respect, it would be convenient to
have a panel of specific monoclonal antibodies targeting
major pathogens, like Pseudomonas, Burkholderia, or Aci-
netobacter. However, as long as such antibodies are not
available for infection imaging, approaches based on the
1D9 antibody could be complemented by other tracers that
target a broad range of pathogens. For instance, many
Gram-positive bacterial pathogens can be detected in vivo
with the vancomycin-800CW tracer that we have previ-
ously developed.13 Infections by Gram-negative bacterial
pathogens can potentially be imaged by making use of fluo-
rescently labeled maltodextrin,24 or by radioactively labeled
metabolizable compounds, like sorbitol.4 On the other
hand, it would also be very useful to develop an additional
humAb that discriminates between MRSA and methicillin-
sensitive S. aureus, as is underscored by the increasing inci-
dence of MRSA infections world-wide.
Altogether, we conclude that the present study has
achieved preclinical proof-of-principle for the use of the
1D9 monoclonal antibody in the in vivo imaging of
infections caused by S. aureus. However, before a clinical
study on the possible use of our 1D9 antibody can be jus-
tified, further animal studies will be needed to answer the
questions how effective the 1D9 antibody will be as a
diagnostic tool for deep-seated S. aureus infections, and
for which clinical indications it is best applied.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains are listed in Supplementary Table 1.
Staphylococci were grown at 37C in Tryptone Soy Broth
(TSB). Escherichia coli Xen14 was grown at 37C in Lysog-
eny Broth (LB; BD Biosciences, Sparks, MD). Lactococcus
lactis PA1001 was grown at 30C in M17 broth (Oxoid
Limited, Hampshire, UK) with 2% glucose. Media were
supplemented with chloramphenicol for plasmid selection
(5 mg/ml for pNG4110 and 10 mg/ml for pLux). Plasmid
pLux (pbp2-pro) from S. aureus ALC290629 was
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introduced by electroporation into S. aureus SH1000 and
MS001 as reported.30,31
Protein expression, LDS-PAGE and Western blotting
Plasmid pNG4110::isaA was constructed by PCR amplifica-
tion of the isaA gene with primers 5 0- atatggatccgctgaag-
taaacgttgatcaag-3 0 and 5 0- atatgcggccgcttagaatccccaagcacct
aaaccttg-3 0, and subsequent cloning in pNG4110.32 Pro-
duction and expression of His6-tagged IsaA from plasmid
pNG4110::isaA was performed as described.32 Bacterial cul-
ture supernatants were precipitated with 10% TCA and
resuspended in LDS sample buffer (Life Technologies,
Grand Island, NY. USA), cells were disrupted with
0.1 mm glass beads (Biospec Products, Bartlesville, USA)
in a Precellys 24 homogenizer (Bertin Technologies,
France), and liberated proteins were resuspended in Lith-
ium Dodecyl Sulphate (LDS) sample buffer. Samples were
analyzed by LDS-PAGE (NuPAGE gels, Life Technolo-
gies) and proteins were visualized by protein staining
(Simply Blue Safe Staining, Life Technologies) or by blot-
ting onto Protan nitrocellulose transfer paper (Whatman,
Germany) and subsequent immunodetection using mouse
anti-His-tag antibodies (Life Technologies) or IRDye
800CW-labeled 1D9 antibody. Fluorescent secondary goat
anti-human or goat anti-mouse IRDye 800CW antibodies
were from LI-COR Biosciences. Antibody binding was
visualized using an Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE. USA).
Antibody production and labeling
The human monoclonal antibody 1D9 was produced as
described22 by transient transfection of Expi293F cells
(Life Technologies). 1D9 antibodies were isolated by
HiTrap Protein A HP column purification (GE Life sci-
ences, Eindhoven, The Netherlands) followed by HiTrap
column desalting (GE Life sciences). 1D9 labeling with
IRDye 800CW (LI-COR Biosciences) was performed as
previously described.33
Human post-mortem implant model
Near-infrared fluorescent imaging of staphylococcal cells
in a human post-mortem model was performed essen-
tially as previously described.13
Mouse model and in vivo fluorescence
and bioluminescence imaging
Maintenance of C57BL/6 mice and intradermal injection
of S. aureus, E. coli or LPS was performed as previously
described.34 In vivo fluorescence and bioluminescence
imaging was performed with an IVIS Lumina III (Perki-
nElmer, Alameda, CA, USA) essentially as previously
described.13 Of note, we injected 5 £ 107 CFUs of S.
aureus to provoke intradermal infection, because our
previous studies have shown that at least 107 CFUs are
needed to establish an S. aureus infection in our mouse
model. Lower numbers of the bacteria will be rapidly
cleared by the murine immune system.
Radiolabeling of 1D9 with 89Zr
Mild conjugation was used to modify 1D9 with a radio-
metal chelate. To antibody in 0.1M HEPES, pH 8.5, three
times was added 10 mL of p-SCN-Bn-Deferoxamine
(DFO; Macrocyclics, Dallas, TX, USA) in DMSO
(233.3 mM) followed by 30–60 min mixing at room tem-
perature to a final DFO:antibody ratio of 7:1. Unreacted
DFO was removed using Amicon Ultra 0.5 mL centrifu-
gal filter 50 kDa (EMD Millipore, Billerica, MA, USA).
89Zr oxalate was obtained from the Mallinckrodt Insti-
tute of Radiology, St. Louis, MO. To 89Zr was added an
excess of 1 M oxalic acid. 0.1M Na2CO3 was slowly
added to a pH of 7-7.5. 89Zr was added to the DFO-con-
jugated antibody and mixed at room temperature for
40 min. To chelate unbound 89Zr, 50 mM EDTA, pH 5,
was added and removed with Amicon Ultra 0.5 mL cen-
trifugal filters using sterile saline. Instant thin layer chro-
matography (ITLC) was performed using silica
impregnated filter paper (Pall Corporation, New York,
NY, USA). ITLC was run in 50 mM EDTA, pH 5, and
subsequently imaged and quantified using a Phosphor-
imager and AutoQuant software (Media Cybernetics,
Rockville, MD, USA).
Nuclear and X-ray imaging
The microPET R4 system (Concorde Microsystems Inc.,
Knoxville, TN, USA) was used to acquire PET scans. For
all static images, scan time was between 10 and 20 min.
Data were sorted into 3D histograms by Fourier rebin-
ning, and transverse images were reconstructed using a
maximum a priori algorithm to a 128 £ 128 £ 63
(0.845 mm £ 0.845 mm £ 1.2115 mm) matrix. Datasets
were analyzed using ASIPro VM microPET software
(Siemens Preclinical Solutions, Erlangen, Germany).
Volumes of interest were manually defined around areas
of bacteria injection and injected activity per gram was
calculated. An empirically determined system calibration
factor for mice was used to convert voxel count rates to
activity concentrations (in mCi per mL of tissue). Figures
were generated using Amira (version 5.0; FEI, Hillsboro,
OR, USA). Directly after PET scanning, while in the
same position, planar images were acquired using the
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MX-20-DC12 digital X-ray imaging system (Faxitron
Bioptics, Tucson, AZ, USA).
Statistical Analysis
Fluorescence imaging data were analyzed with Prism
(GraphPad, La Jolla, CA, USA) and compared using a 1-
tailed Student’s t-test. Values of P<0.05 were considered
significant. All PET imaging data are expressed as mean
§ S.E.M. Data were subjected to the Holm-Sidak
method, with alpha = 0.05 and the assumption that all
rows are sampled from populations with the same scatter
using GraphPad Prism. P-values <0.05 were considered
significant.
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